KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Construction in Progress (2017 - 2018)

Alnylam Pharmaceuticals (ALNY) has disclosed Construction in Progress for 5 consecutive years, with $261.0 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Construction in Progress rose 95.27% year-over-year to $261.0 million, compared with a TTM value of $261.0 million through Dec 2018, up 95.27%, and an annual FY2018 reading of $261.0 million, up 95.27% over the prior year.
  • Construction in Progress was $261.0 million for Q4 2018 at Alnylam Pharmaceuticals, up from $133.6 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $261.0 million in Q4 2018 and bottomed at $2.0 million in Q4 2014.
  • Average Construction in Progress over 3 years is $132.2 million, with a median of $133.6 million recorded in 2017.
  • The sharpest move saw Construction in Progress surged 6978.57% in 2014, then skyrocketed 95.27% in 2018.
  • Year by year, Construction in Progress stood at $2.0 million in 2014, then skyrocketed by 6642.94% to $133.6 million in 2017, then surged by 95.27% to $261.0 million in 2018.
  • Business Quant data shows Construction in Progress for ALNY at $261.0 million in Q4 2018, $133.6 million in Q4 2017, and $2.0 million in Q4 2014.